NVO vs ORMP: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
NVO is the larger of the two ($208.18B market cap): the incumbent the market prices for continued execution (14.37x forward earnings, beta 0.36). ORMP is the smaller challenger ($166.57M), priced similarly on forward earnings (-50.88x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
NVO vs ORMP: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | NVO | ORMP | What it tells you |
|---|---|---|---|
| Market cap | $208.18B | $166.57M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 14.37 | -50.88 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 11.21 | 1.57 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.36 | 1.20 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 41% of range | 65% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 6.72 | 0.70 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how NVO and ORMP affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NVO and ORMP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NVO and ORMP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Novo Nordisk (NVO) do?
Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.
What does Oramed Pharmaceuticals (ORMP) do?
Oramed Pharmaceuticals is a clinical-stage pharmaceutical company focused on the oral delivery of drugs that normally have to be injected. Its core intellectual property is the POD (Protein Oral Delivery) platform, and its best-known candidate is ORMD-0801, an oral insulin capsule aimed at diabetes, with additional early-stage work on an oral GLP-1 (ORMD-0901) and applications such as NASH. Because it has no approved product, Oramed generates little or no product revenue; it has historically funded itself through capital raises and has carried a substantial cash and investment position, including interests and notes tied to other companies, which sets it apart from many cash-strapped micro-cap biotechs.
NVO vs ORMP: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.
- ORMP drivers: Reviving the oral insulin program; Partnerships and restructuring.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise. For ORMP, the dominant risk is clinical failure: Oramed is pre-revenue, its lead program already missed a Phase 3 endpoint, and there is no guarantee a revised trial succeeds or that regulators would approve the product.
NVO or ORMP: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick NVO if you believe its drivers more; ORMP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NVO and ORMP guides.
NVO vs ORMP: the full fundamentals
NVO. Novo Nordisk has historically commanded a premium pharma multiple on the strength of GLP-1 growth and very high margins. The multiple is sensitive to GLP-1 market-share dynamics versus Eli Lilly, supply progress, and US pricing news; disappointing trial data or share loss can compress it quickly. All figures are approximate, are reported in Danish kroner and translated to dollars, and should be verified against the latest filings.
ORMP. Figures are approximate, qualitative, and tied to the asOf date; Oramed is a clinical-stage company whose situation changes with each filing and announcement, so verify live numbers, cash position, and trial status in the latest SEC filings and press releases before acting. Traditional earnings multiples are not meaningful for a pre-revenue biotech; value here reflects the odds of clinical success plus the worth of the balance sheet.
Headline figures (approximate, early 2026): NVO shows revenue (ttm) ~$40 billion (approximate, verify; reported in Danish kroner), operating margin ~45% (approximate, verify), net margin ~35% (approximate, verify), glp-1 share of revenue Majority of sales from semaglutide products (approximate); ORMP shows stage Clinical-stage: minimal or no recurring product revenue, lead asset ORMD-0801 oral insulin (Phase 3 in Type 2 diabetes previously failed its primary endpoints), balance sheet Historically a sizable cash and investment position, including notes/interests tied to other companies; verify the latest figure in filings, profitability Operating losses expected as R&D and trial costs continue; not consistently profitable.
The bottom line: NVO vs ORMP
NVO and ORMP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NVO and ORMP exposure against your real portfolio. It is not an investment adviser.
Wondering how NVO or ORMP fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Novo Nordisk with AI
Connect the broker you already use and ask Walnut's AI how NVO fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between NVO and ORMP?
+
Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Oramed Pharmaceuticals is a clinical-stage pharmaceutical company focused on the oral delivery of drugs that normally have to be injected. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is NVO or ORMP the better stock?
+
Neither is universally better. NVO is the larger incumbent; ORMP is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, NVO or ORMP?
+
On forward P/E (as of August 2026), NVO trades at 14.37x and ORMP at -50.88x, so ORMP is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both NVO and ORMP?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of NVO vs ORMP?
+
NVO: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise. Manufacturing capacity has been a persistent constraint, limiting how much demand it can serve. US drug pricing, payer coverage decisions, and potential price negotiation add reimbursement risk to its largest market. As an ADR, NVO carries Danish krone currency exposure and is influenced by European regulation. Patent expiries and the eventual arrival of biosimilar or generic competition loom over the long-term semaglutide economics. ORMP: The dominant risk is clinical failure: Oramed is pre-revenue, its lead program already missed a Phase 3 endpoint, and there is no guarantee a revised trial succeeds or that regulators would approve the product. Financing and dilution are constant concerns for clinical-stage biotech, since new trials require capital that is often raised by issuing shares. The company's reliance on partnerships adds counterparty and execution risk, as shown when a planned joint venture was terminated after closing conditions went unmet. Part of Oramed's value sits in investments and notes tied to other companies, whose worth can be hard to assess and may be impaired. As a small-cap, the stock can be volatile and thinly followed, and it may move sharply on single announcements. None of this is investment advice.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell NVO or ORMP; figures are approximate and dated (as of August 2026). Verify current data before investing.